Determinants of Type 2 Diabetes Risk in Middle-aged Black South African Men and Women
NCT ID: NCT03408678
Last Updated: 2019-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1025 participants
OBSERVATIONAL
2017-01-23
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Research questions and hypotheses:
1. Does the decrease in sex hormones that occur with ageing increase circulating cortisol and/or inflammatory markers, and directly and/or indirectly via increases in central fat mass, decrease insulin sensitivity in middle-aged black South African men and women?
Hypothesis: The mechanism underlying the decrease in insulin sensitivity (outcome) associated with the decline in sex hormones (exposure) that occurs with ageing is mediated via an increase in centralization of body fat (mediator), which is due to an increase in inflammation and cortisol production.
2. How does HIV alter the relationship between sex hormones, inflammation and cortisol levels, and subsequently body fat distribution and insulin sensitivity?
Hypothesis: HIV infection will exacerbate the effects of the decline in sex hormones with ageing, leading to further increases in inflammation and cortisol production, and a consequent increase in the centralization of body fat and decrease in insulin sensitivity.
3. Does adipose tissue glucocorticoid and inflammatory gene expression differ between pre- and post-menopausal women, with and without HIV, and how do these relate to body fat distribution and insulin sensitivity and secretion?
Hypothesis: Adipose tissue estrogen receptor beta (ERβ), 11-beta hydroxysteroid dehydrogenase type 1 (11HSD1) activity and pro-inflammatory markers will be higher in post- compared to pre-menopausal women, which will be exacerbated by HIV infection. This will be associated with down-regulation of subcutaneous adipose tissue (SAT) adipogenic genes, increased visceral adipose tissue (VAT), a decrease in insulin sensitivity and secretion, and consequently an increased risk for type 2 diabetes (T2D).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gastric Emptying - Implications for the Pathogenesis of Type 2 Diabetes
NCT03864562
Clinical Study on Exploring High Risk Factors Inducing the Progress of Diabetes
NCT05980754
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
NCT05040087
Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes
NCT01494298
Molecular and Clinical Profile of Diabetes Mellitus and Its Complications
NCT01105858
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Part 1 - Using a longitudinal design, a sample of 500 black women at different stages of the menopausal transition, and 500 middle-aged men living in Soweto Johannesburg, South Africa, who were included in previous studies between 2011 and 2014, will be recruited. Socio-demographics, health and menopausal status will be assessed using questionnaires; physical activity and sedentary behaviour will be measured using accelerometry; dietary intake will be estimated using a food frequency questionnaire; body composition and body fat distribution will be assessed using dual energy x-ray absorptiometry (DXA); fasting blood samples will be drawn for the determination of cardio-metabolic risk (glucose, insulin, lipids), cluster of differentiation 4 (CD4) count, as well as sex hormones, inflammatory markers and cortisol concentrations. An oral glucose tolerance test will be performed to measure insulin sensitivity and secretion. Statistical analyses will include multilevel mediation modelling.
Part 2 - Using a cross-sectional design, a sub-sample of 100 women from Part 1 will be selected and divided into four groups including 25 pre-menopausal HIV-negative women and 25 age-matched pre-menopausal HIV-positive women (ARV-Naïve); 25 post-menopausal HIV-negative and 25 age-matched post-menopausal HIV-positive women (ARV-Naïve). The women will undergo a frequently sampled intravenous glucose tolerance test to measure insulin sensitivity and secretion, and adipose tissue biopsies will be taken from the gluteal and abdominal SAT depots for the analysis of gene and protein expression relating to inflammation, sex hormones, glucocorticoid metabolism and adipogenesis. Statistical analyses will include multilevel mediation modelling.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women on whom baseline data was collected between 2011 and 2014 as part of the Study of Women Entering and in Endocrine Transition.
* Men on whom baseline data was collected in 2014 as part of a larger African genomics study (www.h3Africa.org).
Part 2: A sub-sample of women from Part 1 of the study:
* Pre-menopausal women age-matched within the age range 35-45 years;
* Post-menopausal women age-matched within the age range 55-65 years;
* All women: BMI 25-40 kg/m2
Exclusion Criteria
\- Failed to consent to participate in the study.
Part 2:
* Diabetes, thyroid dysfunction, inflammatory, hepatic and renal diseases;
* Use of hormone replacement therapy; hormonal contraceptives, oral cortisone, anti-inflammatory drugs or antiretroviral therapy;
* Peri-menopausal;
* Currently pregnant or lactating;
* Tobacco use.
35 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Research Council, South Africa
OTHER
GlaxoSmithKline
INDUSTRY
University of Oxford
OTHER
University Hospital, Umeå
OTHER
University of Witwatersrand, South Africa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julia Goedecke
Honorary Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia H Goedecke, PhD
Role: PRINCIPAL_INVESTIGATOR
Medical Research Council, South Africa
Lisa K Mickelsfield, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Witwatersrand, South Africa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SAMRC/WITS Developmental Pathways of Health Research Unit, University of Witwatersrand
Johannesburg, Gauteng, South Africa
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M160604
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.